From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Stocks I still love include Tate & Lyle and James Halstead

By Chris Bailey | Thursday 31 March 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


As noted back in November, I am a fan of Tate & Lyle (TATE) shares so it is pleasing to see them up 8% odd year-to-date. There are a bunch of reasons for this as I observed nearly five months ago, but the news today is that it’s buying a “leading prebiotic dietary fibre business in China from ChemPartner Pharmatech Co., Ltd for a total consideration of US$237 million”. It is far from a boring thing to do, in fact – for a company which is outsourcing the management of much of its core historic business shortly – it is actually quite interesting to help it access more of the Asian/emerging market world over time. I remain a fan. And what also about James Halstead (JHD), “the AIM listed manufacturer and international distributor of commercial floor coverings”, whose shares are most certainly not up year-to-date?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

Time left: 08:42:10